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Abstract: MISME syndrome, also known as neurofibromatosis type-2 (NF2), stands for 
multiple inherited schwannomas, meningiomas, and ependymomas (MISME) in the 
peripheral and central nervous system. It is a rare disorder of autosomal dominant 
inheritance due to mutations of a tumor-suppressor gene on the chromosome 22q12. 
Clinically, it is characterized by multiple benign tumors arising in both the central and 
the peripheral nervous system, particularly from the bilateral vestibular nerve in more 
than 90% of the patients and more than two thirds of them develop spinal tumors. 
Simultaneous occurrence of bilateral vestibular schwanoma with cervical and lumbar 
ependymoma without neuro cutaneous marker with weakness of limb as initial 
presentation is rare finding in single patient. Here, we are reporting a rare case of MISME 
syndrome harbouring bilateral vestibular schwanoma with cervical and lumbar 
ependymoma tumors in a 45 year old male patient having no other lesion and 
neurocutaneous marker with weakness of limb as initial presentation without posterior 
subcapsular cataract. 
Key words: Ependymoma, Meningioma, Neurofibromatosis type 2, MISME Syndrome, 
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Introduction 
Neurofibromatosis (NF) is a syndrome of 
an autosomal dominant inheritance. NF is 
divided into two types: NF1 and NF2. NF1, 
formerly known as von Recklinghausen 
disease, is caused by mutations of 
neurofibromin gene on the long arm of 
chromosome 17. NF1 is one of the most 
common single-gene disorders affecting 
neurological function in humans (3).  
NF2, also known as the MISME syndrome 
is caused by mutations of "Merlin" gene on the 
chromosome 22q12. NF2 is a rare genetic 
disorder with multiple benign nervous system 
tumors, so as named as MISME syndrome (1, 
10, 12) Although NF1 and NF2 are associated 
with autosomal dominant inheritance, up to 
half of NF1 and NF2 patients are due to 
spontaneous mutation. The incidence is about 
1 in 3500 live births for NF1 and 1 in 60,000 
for NF2(5). It has no predilection for race, sex 
and ethnicity (2).   
Although, simultaneous occurrence of the 
bilateral vestibular schwanoma with cervical and 
lumbar ependymoma in an individual can be 
uncommonly encountered, occurrence of 
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bilateral vestibular schwanoma with cervical and 
lumbar ependymomas with weakness of limb as 
initial presentation without posterior subapsular 
cataract in a single patient is a rare finding. 
Case Report 
A 45 yr old male patient presented to our 
outpatient department with the chief 
complaints of upper motor neuron type 
weakness of left side of upper limb and lower 
limb for 15 years, which was of insidious onset 
with initial progression and later non 
progressive course. His other complaints were 
hearing loss and tinnitus in the left ear for last 6 
years, headache in left sub occipital region for 5 
years, hearing loss with tinnitus in right ear for 
2 yrs, swaying on either side while walking or 
difficulty in speech for last 6 months. There is 
no family history of similar disease which 
suggests that it is a sporadic case. Neurological 
examination revealed decrease in sensation on 
left side face with absent corneal reflex on left 
side left lower motor neuron type seventh 
cranial palsy(House and Brackmann grade 
3),and bilateral sensory neural hearing 
loss(left>right) and left 9th and10th cranial 
nerve palsies. Motor examination revealed 
increase tone in all four limbs (Modified 
Ashworth Score -1). Power of the left side upper 
limb and lower limb was 4/5 and in right side 
upper and lower limb was 5/5 and it is non 
progressive in last 10 years. Deep tendon 
reflexes are 3+ in all four limbs; planter was 
extensor bilaterally. Sensations of touch and 
pinprick were decreased by 50% below C3 level.  
Pure tone audiometry was suggestive of 
bilateral sensory neural deafness more on left 
side. Ophthalmic evaluation revealed bilateral 
mild papiloedema with no subcapsular 
lenticular opacities. Magnetic resonance 
imaging (MRI) of brain was showing a mass 
lesion present in left cerebellopontine angle 
(CP angle) cistern (Figure 1A). Mass was 
causing compression of brainstem. There is 
another smaller lesion on right CP angle 
cistern (Figure 1A). MRI of Spine revealed a 
well-defined intramedullary lesion at C3-C4 
(Figure 1B) and another lesion at L1 region 
(Figure 1C).  
We performed the microscopic subtotal 
excision of left CP angle lesion through 
retrosigmoid sub occipital approach as it was 
causing significant brainstem compression and 
planned right CP angle lesion for staged 
resection at later stage. As cervical and lumbar 
lesions were not causing progression of 
symptoms for years, we left it and follow up is 
planned. Histopathology report of left CP angle 
lesion revealed it was vestibular Schwannoma 
(Figure 3). Post-operative scan suggestive of near 
total excision of left CP angle lesion (Figure 2). 
There is no further deterioration of cranial nerve 
palsies post operatively. 
 
 
Figure 1A 
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Figure 1B 
 
Figure 1C 
Figure 1A - Showing mass lesion in both CP angle 
region with heterogeneous contrast enhancement 
and brain stem compression on left side. Figure 1B 
and 1C - Showing mass lesion at C3-C 4 and L1 level 
 
 
Figure 2 - Post-operative image suggestive of near 
total excision of left CP angle lesion 
 
Figure 3 - Histopathology suggestive of schwanoma 
Discussion 
MISME Syndrome is synonymous with 
Neurofibromatosis (NF) type 2 
Neurofibromatosis is a condition with 
autosomal dominant inheritance 
characterized by presence of multiple spaces 
occupying lesion in central and peripheral 
nervous system. The first probable reported 
case of neurofibromatosis type 2 was that of 
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Wishart in 1820 (18). This patient had 
multiple intracranial tumours with no 
cutaneous features and was, therefore, 
different to those patients reported by von 
Recklinghausen in 1882 (17), whose principal 
features were nodular skin lesions with no 
intracranial tumours. Later authors reported 
cases of neurofibromatosis type 1 with 
intracranial tumours and neurofibromatosis 
type 2 with cutaneous features (9, 4). In 
reporting a large family with 
neurofibromatosis in 1930, Gardner and 
Frazier (6) suggested that bilateral acoustic 
neuromas represented a separate central form 
of von Recklinghausen neurofibromatosis. 
 NF was classified as two types based on 
their clinical and pathological features (9). NF 
1 caused by defect in neurofibromin gene 
which is located on long arm of chromosome 
17, whereas NF 2 caused by mutations in 
merlin gene located on long arm of 
chromosome 22. This merlin gene is a tumor 
suppressor gene, which maintains cell 
connection of cytoskeleton with the plasma 
membrane, there by controls shape, motility of 
cell as well as growth regulation (5). It has 
almost 90% clinical penetrance rate. 
The diagnosis of NF2 usually made in 2nd 
and 3rd decades of life, mostly 18 to 24 yrs of 
age (5). Diagnostic criteria which confirms 
diagnosis of NF2 is A) Bilateral 8th cranial 
nerve schwannomas on imaging or B) First 
degree relative with NF2 and unilateral 8th 
cranial nerve schwannoma at <30 yrs or any 
two of following: Glioma, Neurofibroma, 
Schwannoma, Meningioma, Juvenile posterior 
subcapsular lenticular opacity. The criteria for 
presumptive or probable diagnosis of NF2 are 
A) unilateral 8th cranial nerve Schwannoma 
<30 yrs and: Glioma, Schwannoma, 
Meningioma or posterior subcapsular cataract 
or cortical cataract. B) Multiple Meningiomas 
(Two or More) and unilateral vestibular 
Schwannoma <30 yrs or at least one of Glioma, 
Schwannoma, Juvenile posterior subcapsular 
cataract (7, 14, 15) 
Almost more than 90% cases of NF2 will 
develop bilateral 8th cranial nerve 
schwannomas. In literature occurrence of 
schwannomas from other cranial nerves like 
Trigeminal, Occulomotor, Trochlear and 
Abducens nerves have been described 
previously. The most common type of spinal 
tumor in NF2 is schwannomas. Most common 
site is cervico thoracic region originating from 
dorsal root. 50 to 75% of NF2 patients develop 
meningiomas, most commonly in supra 
tentorial location. 
Histopathologically mostly they are 
fibroblastic type. In spinal cord, meningiomas 
are mostly seen in thoracic Region. 
Ependymomas are seen in intramedullary 
location of conus medullaris or cervical region. 
Approximately 90% of NF2 patients had 
ocular lesions.  
Neurological examination and imaging of 
craniospinal axis is crucial to establish a 
diagnosis.  Mautner et al published a case 
series of 48 NF2 patients regarding their 
prevalence of various lesions in 1996(13). He 
concluded that 46 patients had 8th cranial 
nerve schwannomas (96%, 43 bilateral and 03 
unilateral), 43 patients (90%) had Spinal 
tumors, 30 patients (63%) had posterior 
subcapsular cataracts, 28 patients (58%) had 
meningiomas, and Trigeminal schwannomas 
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were present in 14 (29%) patients. MR imaging 
of brain and spine with contrast is the 
investigation of choice in NF2 patients. NF2 
patients should be managed by 
multidisciplinary approach which includes a 
neurologists, neurosurgeons, 
neuroradiologists, ophthalmologist, geneticist, 
audiologists and otologists. Every child with 
family history of NF2 should be screened with 
imaging of brain and spine as early as possible 
from 10 to 12 years with annual scans until 4th 
decade.  
Management in NF2 patients is 
preservation of function rather cure as they 
have lifelong tendency to develop new tumors 
and or recurrences. NF2 related 8th cranial 
nerve schwannomas are difficult to manage as 
they are often large by the time they are 
diagnosed and tend to behave aggressively. 
Symptomatic Vestibular schwannomas should 
be treated early to preserve auditory and other 
cranial nerve functions. There are various 
modalities for treatment of vestibular 
schwannomas in NF2. Single or multiple 
fraction stereotactic radio surgery advocated at 
some centres with good local control and low 
incidence of side effect. Regardless of 
approach all centers agree that intervention 
should be done only if there is documented 
tumor growth or progressive hearing loss. 
Surgical options include radical resection, 
partial removal and decompression. We prefer 
a suboccipital retrosigmoid approach with 
goal of preserving facial nerve and hearing. 
There was significant brainstem compression 
in our case on one side so we did subtotal 
removal of mass lesion to relive compression 
from brainstem. We planned staged resection 
for the contalateral tumor. Early surgery is 
advocated if vestibular tumor is less than 1.5 
centimetres (cms) in diameter to preserve 
hearing and facial nerve function. If size is 
more than 1.5 cms it is preferred to wait until 
there is motor dysfunction due to brainstem 
compression. Cochlear implants, hearing aids 
and auditory brainstem implants are 
alternative modes of treatment for complete 
hearing loss (16, 11). Menengioma in NF2 are 
removed for cortical compression causing 
neurological deficit or seizure activity. Surgical 
removal of intramedullary spinal tumor is 
recommended only when there are sign of 
spinal cord compression. Hydrocephalus is 
treated with either direct tumor removal or 
ventriculoperitoneal shunt before definitive 
surgery. 
Conclusion 
MISME syndrome, or NF2, is not a curable 
disease. Limited usefulness of adjuvant 
therapy leaves surgery as primary treatment to 
alleviate symptoms. Surgery should be limited 
to removal of tumour that are causing 
symptoms. Surgical approaches to tumors of 
NF2 is generally similar to the approach of 
same tumor in patients without NF2. 
However, the decision of when to operate and 
what level of aggressiveness is required, is 
often of critical importance in NF. Even 
though the relentless progression of disease 
may be discouraging many times, ability of 
neurosurgical procedures to alleviate 
symptoms and improve quality of life is 
significant. 
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